At last year’s AD/PD meeting in Vienna, what is now the Consortium for Biomedical Research and AI in Neurodegeneration was an idea. By this year’s AD/PD in Copenhagen, C-BRAIN had become an operating ...

Once more than 4 percent of tau molecules in a person’s blood are phosphorylated at residue 217, the clock starts ticking—toward the first symptoms of Alzheimer’s disease, that is. How long it might ...

Exercise helps stave off Alzheimer’s disease, but exactly how it does so is murky. In the February 18 Cell, scientists led by Saul Villeda at the University of California, San Francisco, offered one ...

Geneticists studying Alzheimer’s disease need tools to help them pinpoint causal risk variants, the majority of which lurk in noncoding regions. In the February 13 Science Advances, Di Huang and Ivan ...

Post-marketing data chart immunotherapy performance in early-onset Alzheimer’s. The antibodies lowered amyloid and slowed functional decline. However, tangles continued to form. “These results offer ...

According to a recent study, the view that Alzheimer’s disease damages the brain irreversibly might need to change. In December 22 Cell Reports Medicine online, scientists led by Andrew Pieper of Case ...

More antibodies take aim at seeded propagation. New data ties tangle location to deficits in specific cognitive domains. Three first-in-human studies for antibodies targeting different parts of tau ...

In a small, open-label trial in people with mild to moderate, dominantly inherited Alzheimer’s disease (DIAD), the tau immunotherapy etalanetug almost abolished markers of neurofibrillary tangles in ...

The days when reading a few papers brought scientists up to speed on the developments in their field are gone. Now scientists face mounting volumes of deeply complex datasets, and not remotely enough ...

Talk about a closely watched study. Conference after conference, Roche scientists running the ongoing Brain Shuttle AD trial of trontinemab are dispensing morsels of news from sequential interim ...

For years, scientists have been working toward blood tests for Alzheimer’s disease that could be used routinely in clinical practice. Now, they are on the cusp. At this year’s ADPD conference, held ...

Cerebrospinal fluid and plasma markers are now being used to help diagnose Alzheimer’s in memory clinics, but what about using them to stage the disease? That’s the next big step, said Henrik ...